Source comparison
Mechanism of Action — Central vs Peripheral Pathways
Viagra operates exclusively at the vascular level. Sildenafil citrate. The active molecule. Selectively inhibits PDE5, the enzyme responsible for breaking down cyclic guanosine monophosphate (cGMP) in smooth muscle cells lining penile arteries. When cGMP accum
This comparison does not assign a generated winner or score.
- Viagra operates exclusively at the vascular level. Sildenafil citrate. The active molecule. Selectively inhibits PDE5, the enzyme responsible for breaking down cyclic guanosine monophosphate (cGMP) in smooth muscle cells lining penile arteries. When cGMP accumulates, smooth muscle relaxes, arterial dilation occurs, and blood flow into the corpora cavernosa increases. This mechanism is downstream of arousal. It amplifies the hemodynamic response to sexual stimulation but does not initiate desire or neurological arousal signaling.
- PT-141 acts on melanocortin receptors (primarily MC3R and MC4R) located in the hypothalamus and other central nervous system regions involved in sexual motivation. Activation of these receptors modulates dopamine and oxytocin pathways, which govern sexual desire and arousal independent of genital blood flow. The compound is a synthetic cyclic heptapeptide derived from melanotan II, originally studied for its effects on skin pigmentation before its central effects on sexual function became apparent in Phase 1 trials.
- The practical implication: Viagra requires intact vascular responsiveness. PT-141 does not. Patients with severe endothelial dysfunction, diabetes-related vascular damage, or surgical nerve disruption may experience little benefit from PDE5 inhibition. The mechanism depends on functional nitric oxide signaling. PT-141 bypasses this pathway entirely, which is why it shows efficacy in populations where Viagra does not.
- Clinical trial data from RECONNECT studies (published in Obstetrics & Gynecology, 2019) demonstrated statistically significant improvement in sexual desire and distress scores in premenopausal women. A population for whom PDE5 inhibitors show minimal effect. Viagra's mechanism is sex-agnostic at the molecular level but clinically ineffective in addressing desire disorders because it acts peripherally, not centrally.